Two lead compounds with:
Candidate derivatives have the potential to be used as long-acting anti-HIV agents for HIV treatment and prevention with potential value-added over the current HIV prevention portfolio.
The compounds and their antiviral activities are protected by multiple patents1 2 3.
A number of compounds are under development using a similar strategy against SARS-CoV-2.
1 Parang, K., Tiwari, R, El-Sayed, N. S. Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals. April 30, 2020, Provisional Patent Application number 63/017,729.
2 Parang, K., Tiwari, R, El-Sayed, N. S. Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals. July 17, 2020, Provisional Patent Application number 63/053349.
3 Parang, K., Doncel, G., Agarwal, H. K. Substituted nucleoside derivatives with antiviral and antimicrobial properties (Divisional Composition and method claims). PCT Patent filed on March 24, 2016 (15/079,918). U.S. Patent Application 2016, 15/079,918, U.S. Patent No. 9,738,678, August 22, 2017.